Longevity Health Holdings Reports Revenue Growth and Reduced Net Losses in Q1 2025

Longevity Health Holdings, Inc. reported its financial results for the first quarter of 2025, revealing a significant increase in revenue and a reduction in net losses compared to the previous year. The company generated gross sales of $534,943, leading to net sales of $510,353 after accounting for discounts and allowances. This marks a substantial increase from zero sales reported in the same period last year, reflecting the impact of the Elevai Acquisition completed in January 2025. The cost of sales for the quarter was $240,530, resulting in a gross profit of $269,823.

In terms of operating expenses, Longevity Health Holdings incurred a total of $1,776,574, which is a 29% increase from $1,380,345 in the prior year. The rise in expenses was primarily driven by selling and marketing costs of $280,549, which were non-existent in the previous year, and an increase in general and administrative expenses, which rose to $1,275,161 from $927,394. Research and development expenses decreased significantly to $196,912 from $429,420, reflecting the company's strategic shift to focus on products with near-term commercial potential. The net loss for the quarter was $1,505,867, a 54% improvement from the $3,270,959 loss reported in the same quarter of 2024.

The company’s balance sheet showed total assets of $3,337,234 as of March 31, 2025, compared to $1,473,980 at the end of 2024. This increase was largely due to a rise in current assets, particularly inventory, which surged to $1,379,640 from $108,705. However, total liabilities also increased to $7,142,519 from $6,186,642, with current liabilities rising significantly, primarily in accounts payable. The company reported a stockholders' deficit of $3,805,285, an improvement from $4,712,662 at the end of 2024.

Strategically, Longevity Health Holdings has made notable moves, including the Elevai Acquisition, which is expected to enhance its product offerings in the skincare and haircare markets. The company also executed a reverse stock split at a ratio of 1:30, effective May 12, 2025, aimed at improving its stock price and compliance with Nasdaq listing requirements. Additionally, the company is pursuing a merger with 20/20 Biolabs, which is contingent upon raising at least $4 million in financing. The management has expressed optimism about the future, focusing on the commercialization of its products and exploring additional capital-raising opportunities to ensure liquidity and operational continuity.